Danish Software Stock News

FDA approves Novo Nordisk's once daily Wegovy pill for weight management and cardiovascular risk reduction in the U.S. The company begins an early U.S. launch with distribution through channels including Amazon and Costco, alongside telehealth partners. Initial prescription demand is described as strong, indicating broad patient interest in an oral alternative to injectable GLP 1 therapies. Novo Nordisk, ticker CPSE:NOVO B, also faces new legal challenges, including a U.S. class action and...

A.P. Møller - Mærsk (CPSE:MAERSK B) is back in focus after renewed security risks in the Red Sea, as Houthi attacks prompt shipping firms to reroute vessels, extend transit times and reassess operational risk. See our latest analysis for A.P. Møller - Mærsk. The renewed Red Sea risk is arriving at a time when A.P. Møller - Mærsk’s shares have already shown stronger momentum, with a 90 day share price return of 8.92% and a 1 year total shareholder return of 61.55%. This points to building...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

In January 2026, Genmab reported that worldwide 2025 net trade sales of DARZALEX, as reported by Johnson & Johnson, reached US$14.35 billion, generating ongoing royalty revenue for Genmab, and released positive topline Phase 3 EPCORE DLBCL-1 results showing epcoritamab monotherapy improved progression-free survival in relapsed or refractory DLBCL versus standard regimens. The combination of a very large, royalty-generating DARZALEX franchise and clinically meaningful Phase 3 data for...

Danske Bank (CPSE:DANSKE) has launched a substantial new share buy-back programme. The bank has also introduced its first forward guidance for 2026. These steps are part of a newly implemented long term strategy. Danske Bank comes into this announcement with shares at DKK325.6 and a strong recent track record in the market. The stock is up 3.9% over the past week and 3.1% over the past month, with a 1.9% gain year to date. Over the past year, the share price has risen 59.8%, and over three...

What recent returns suggest about AL Sydbank AL Sydbank (CPSE:ALSYDB) has caught investor attention after a strong 1 year total return of 58.97%, alongside positive moves over the past week, month and past 3 months, all from a recent closing price of DKK 566.50. See our latest analysis for AL Sydbank. That 1 year total shareholder return of 58.97%, together with positive short term share price returns in recent weeks, points to momentum that has gradually built rather than a sudden jump from...

Vestas Wind Systems (CPSE:VWS) is back in focus after European countries agreed on plans for 100 GW of shared offshore wind capacity in the North Sea, and Vestas shares rose 5.2% on the news. See our latest analysis for Vestas Wind Systems. The North Sea pact has arrived on top of a strong run in Vestas’ shares, with a 90 day share price return of 46.61% and a 1 year total shareholder return of 103.98% from a starting point that had seen weaker multi year outcomes. Recent gains, including a...

A.P. Møller - Mærsk has resumed part of its Red Sea–Suez Canal sailings with conditional routing, while also appointing Charles van der Steene as Regional Managing Director for the Indian Subcontinent, Middle East & Africa from 1 January 2026 and progressing a share buy-back program of up to DKK 14.40 billion announced in February 2025. Together, these developments highlight Maersk’s mix of operational risk management, regional leadership continuity and capital return decisions at a time of...

Amid renewed trade and geopolitical uncertainty, the European stock market has seen declines, with the pan-European STOXX Europe 600 Index ending 0.98% lower. Despite these challenges, business activity in the eurozone remains positive, offering a glimmer of optimism for investors seeking opportunities in undervalued stocks. In this context, identifying stocks trading below their intrinsic value can be crucial for investors looking to capitalize on potential market inefficiencies and position...

Share buy-back launch puts Aktieselskabet Schouw (CPSE:SCHO) in focus Aktieselskabet Schouw (CPSE:SCHO) has moved into the spotlight after launching a share buy-back programme of up to DKK 240 million through 2026, a capital allocation decision that can influence both valuation and trading interest. See our latest analysis for Aktieselskabet Schouw. That buy-back announcement lands after a steady run in the share price, with a 30-day share price return of 4.67% and a 90-day share price return...

Why this new Swiss facilities contract matters for ISS (CPSE:ISS) ISS (CPSE:ISS) has secured a full Integrated Facility Services contract in Switzerland, shifting from subcontractor to primary partner for a large life sciences and pharmaceutical client across four sites. The agreement, worth close to DKK 300 million per year over an initial three-year term with an option for two more years, adds a sizeable, multi-year client relationship to ISS’s existing facilities management portfolio. See...

With a median price-to-sales (or "P/S") ratio of close to 0.7x in the Healthcare industry in Denmark, you could be...

Event driven focus on Demant’s evolving platform Demant (CPSE:DEMANT) is refocusing around a comprehensive audio healthcare platform. The platform is built on custom chipsets, on device AI, and an integrated retail and diagnostics footprint that ties hardware, software, and clinical services together. See our latest analysis for Demant. At a DKK233.2 share price, Demant’s recent 1 month share price return of 8.97% and year to date share price return of 9.28% sit against a 1 year total...

Why Novozymes is on investors’ radar today Novozymes (CPSE:NSIS B) is back in focus after recent share price moves. The stock has shown positive returns over the past month and the past 3 months, prompting investors to reassess its current valuation and fundamentals. See our latest analysis for Novozymes. Beyond the recent uptick, Novozymes has a 3.4% year to date share price return and a 22.34% three year total shareholder return, which points to steady momentum rather than a sharp short...

The Board of Directors of Alm. Brand (CPSE:ALMB) has recommended an ordinary dividend of DKK 0.66 per share for the 2025 financial year, corresponding to a total payout of DKK 0.9b. See our latest analysis for Alm. Brand. At a share price of DKK18.16, Alm. Brand has had a mildly weaker recent patch, with a 1 month share price return of a 3.51% decline, even though its 1 year total shareholder return of 25.93% points to momentum that has built over a longer horizon. If this dividend news has...

What Ringkjøbing Landbobank’s new guidance and buyback could mean for shareholders Ringkjøbing Landbobank (CPSE:RILBA) has set 2026 net profit expectations at DKK 2.0b to DKK 2.4b and backed this outlook with a Board approved share repurchase program of up to DKK 500m. For you as an investor, that combination of earnings guidance and buyback authorization gives two concrete reference points: what management currently expects the business to earn, and how much capital it is prepared to commit...

In recent weeks, Novo Nordisk’s newly launched oral Wegovy weight-loss pill has seen strong early U.S. uptake, with more than 18,000 prescriptions written in its first full week on the market. This rapid adoption highlights physician and patient appetite for a more convenient oral GLP-1 option and may reinforce Novo Nordisk’s competitive positioning in obesity care. We’ll now examine how this rapid uptake of the oral Wegovy pill could influence Novo Nordisk’s broader investment narrative...

With its stock down 12% over the past month, it is easy to disregard Zealand Pharma (CPH:ZEAL). However, a closer look...

Danske Bank has recently updated its outlook, keeping a solid profit forecast for 2025 but signalling lower earnings expectations for 2026 as it rolls out a long-term strategy toward 2030 that is expected to press on shorter-term results. This shift highlights how management is prioritising a multi‑year transformation, accepting near‑term profit pressure to reshape operations and reposition the bank for its 2030 ambitions. We will now examine how Danske Bank’s decision to accept weaker 2026...

Coloplast A/S' ( CPH:COLO B ) price-to-earnings (or "P/E") ratio of 33.6x might make it look like a strong sell right...

A.P. Møller - Mærsk (CPSE:MAERSK B) is structurally returning to its Red Sea Suez Canal route, resuming transits through the corridor despite ongoing regional security concerns. The change affects how Maersk routes a portion of its Asia Europe and related services, shifting some traffic back from longer alternative routes. This decision comes as other global carriers continue to use rerouting options around Africa in response to the same security risks. For you as an investor, this move...

How Genmab’s recent performance frames the story for investors Genmab (CPSE:GMAB) has drawn fresh attention after a period where the stock delivered a 0.6% gain over the past month and 11.5% over the past 3 months, alongside double digit annual revenue and net income growth. See our latest analysis for Genmab. At a share price of DKK2130.0, Genmab’s recent 11.49% 3 month share price return sits alongside a 41.72% 1 year total shareholder return. However, the 3 and 5 year total shareholder...

In January 2026, SSEN Transmission confirmed it has signed final contracts with NKT for two 525 kV HVDC power cable projects in Scotland, adding around €2.00 billion of turnkey design, production and on/offshore installation work to NKT’s high-voltage order backlog. Alongside this, NKT’s launch of the KFEV 245 dry-type outdoor termination highlights how the company is expanding into safer, oil-free high-voltage accessories that address growing environmental and installation concerns in...

The recent installation of the last turbine at Ørsted (CPSE:ORSTED) Greater Changhua 2b and 4 offshore wind farms in Taiwan has sharpened investor focus on how these Asia Pacific projects might influence the stock. See our latest analysis for Ørsted. Ørsted shares have gained momentum recently, with a 30 day share price return of 16.05% and a year to date share price return of 7.62%. This comes even though the 1 year total shareholder return is a 6.86% decline and the 5 year total shareholder...